Companies › Oncolytics Biotech
1 active drug program in 5 registered trials: 3 Phase 2, 2 Phase 1; Oncology; next expected readout Jul 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Pelareorep Oncolytic reovirus | – | Phase 2 | Breast Cancer Metastatic; Ras-mutated Metastatic Colorectal Cancer; Anal Cancer Metastatic; Anatomic Stage IV Breast Cancer AJCC v8 … | Jul 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT04215146 | Pelareorep | Phase 2 | Breast Cancer Metastatic | Oncology | Aug 2022 |
| NCT04445844 | Pelareorep | Phase 2 | Anatomic Stage IV Breast Cancer AJCC v8 | Oncology | Jun 2025 |
| NCT05514990 | Pelareorep | Phase 1 | Recurrent Plasma Cell Myeloma | Oncology | Dec 2026 |
| NCT07280377 | Pelareorep | Phase 1 | Anal Cancer Metastatic | Oncology | Jul 2027 |
| NCT07446322 | Pelareorep | Phase 2 | Ras-mutated Metastatic Colorectal Cancer | Oncology | Aug 2027 |
Cash of $4m on 2026-06-30; operating cash outflow about $31m a year; runway about 2 months at that burn, to Aug 2026; 0 of 1 coming phase 2-3 readouts fall inside that runway
Press releases filed as 8-K in the last year:
No annotated target.
–
Cardiff Oncology TuHURA Biosciences Actuate Therapeutics Inhibrx Biosciences Genelux
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.